Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is poised for success as a molecular diagnostics company due to their revolutionary QCT molecular counting platform and diverse portfolio of ultrasensitive tests for prenatal genetic testing, cancer therapy selection and response monitoring. Their strong positioning in the market, partnerships with major payors, and focus on higher rates rather than easier access for physicians make them a promising investment. Additionally, the company's profitability and plans for growth initiatives indicate a sound financial foundation for future success.

Bears say

BillionToOne is facing potential limitations and competition in key markets, including the prenatal testing market, therapy selection market, and the highly competitive pipeline markets of MRD and Early Detection. The company's rapid growth and positive financial metrics can be attributed to its conservative decision-making culture and the QCT platform, but these may not be enough to sustain growth in the long term, especially with increased competition and market limitations.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.